<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680795</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-BEL-106</org_study_id>
    <nct_id>NCT02680795</nct_id>
  </id_info>
  <brief_title>Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes</brief_title>
  <official_title>Open-label, Nonrandomized, Phase 1 Study Evaluating Safety and Pharmacokinetics of Belinostat in Patients With Relapsed/Refractory Solid Tumors or Hematological Malignancies in Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acrotech Biopharma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Axis Clinicals Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acrotech Biopharma LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, nonrandomized study to determine the PK profiles of belinostat&#xD;
      in patients with relapsed/refractory solid tumors or hematological malignancies who have&#xD;
      heterozygous and homozygous UGT1A1*28 genotypes and wild-type UGT1A1 gene. Enrolled patients&#xD;
      will be assigned to 1 of 3 cohorts (A, B, or C) based on their UGT1A1 genotype&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, nonrandomized study to determine the PK profiles of belinostat&#xD;
      in patients with relapsed/refractory solid tumors or hematological malignancies who have&#xD;
      heterozygous and homozygous UGT1A1*28 genotypes and wild-type UGT1A1 gene. Enrolled patients&#xD;
      will be assigned to 1 of 3 cohorts (A, B, or C) based on their UGT1A1 genotype&#xD;
&#xD;
      Enrollment into all cohorts will occur simultaneously rather than sequentially. Belinostat&#xD;
      will be administered via a 30-minute infusion once daily from Day 1 to Day 5 of one 21-day&#xD;
      cycle. Clinical safety will be monitored in each patient. Blood samples for PK analysis will&#xD;
      be collected from Day 1 to Day 3, and urine samples for PK analysis will be collected from&#xD;
      Day 1 to Day 4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2016</start_date>
  <completion_date type="Actual">July 21, 2020</completion_date>
  <primary_completion_date type="Actual">July 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma and urine concentrations of belinostat will be measured</measure>
    <time_frame>26 Weeks</time_frame>
    <description>PK will be measured for area under the time-concentration curve (AUC), steady state volume of distribution (Vdss),PK will be measured for total body clearance (CLtot),PK will be measured for fraction excreted unchanged (fe), PK will be measured for renal clearance (CLren), PK will be measured for non-renal clearance (CLnonren), PK will be measured for peak concentration (Cmax),and half-life (t1/2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess overall incidence of treatment emergent adverse events (TEAEs) using CTCAE version 4.03</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Assess Safety of belinostat in patients with wild type, heterozygous, and homozygousUGT1A1*28 genotypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess any adverse events (AEs) (changes in physical exam or laboratory findings related to study medication dosing</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Assess Safety of belinostat in patients with wild type, heterozygous, and homozygousUGT1A1*28 genotypes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>Wild Type UGT1A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A: Open for Enrollment Wild Type UGT1A1, Belinostat IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous UGT1A1*28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B: Closed For Enrollment Heterozygous UGT1A1, Belinostat IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous UGT1A1*28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C: Open For Enrollment Homozygous UGT1A1, Belinostat IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belinostat IV</intervention_name>
    <description>Cohort A:&#xD;
Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.&#xD;
Cohort B:&#xD;
Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.&#xD;
Cohort C:&#xD;
Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.</description>
    <arm_group_label>Heterozygous UGT1A1*28</arm_group_label>
    <arm_group_label>Homozygous UGT1A1*28</arm_group_label>
    <arm_group_label>Wild Type UGT1A1</arm_group_label>
    <other_name>Beleodaq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is diagnosed with advanced solid tumors or advanced hematological malignancy&#xD;
             that is relapsed/refractory, for which no standard salvage therapy exists.&#xD;
&#xD;
          2. Patient must have received at least 1 prior systemic therapy for the current&#xD;
             malignancy and has recovered from any toxicity of the prior therapy at screening.&#xD;
&#xD;
          3. Patient has adequate hematological and hepatic functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is taking UGT1A1 inhibitors (eg, atazanavir, gemfibrozil, indinavir,&#xD;
             ketoconazole, sorafenib) at screening.&#xD;
&#xD;
          2. Patient has HBV or HCV&#xD;
&#xD;
          3. Patient has a known HIV positive diagnosis.&#xD;
&#xD;
          4. Patient has congestive heart failure Class III/IV&#xD;
&#xD;
          5. Patient has had previous exposure to belinostat.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wasim Khan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acrotech Biopharma LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Wayne Cancer Institute @ Providence Saint John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UGT1A1*28</keyword>
  <keyword>Belinostat</keyword>
  <keyword>beleodaq</keyword>
  <keyword>wild type genotypes</keyword>
  <keyword>heterozygous genotypes</keyword>
  <keyword>homozygous genotypes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

